ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

587
Analysis
Health CareChina
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
bullishWuXi XDC Cayman
18 Jul 2023 09:33

WuXi XDC Cayman Pre-IPO Tearsheet

WuXi XDC Cayman Inc (1877628D HK) is looking to raise >US$100m in its upcoming Hong Kong IPO. The bookrunners on the deal are Morgan Stanley,...

Logo
604 Views
Share
bullishWuXi XDC Cayman
17 Jul 2023 08:55

Pre-IPO WuXi XDC - The Beautiful Story and the Truth Behind

How far WuXi XDC can go in the future depends on the real market space of ADC and the company's performance. But as a capital operation, good story...

Logo
619 Views
Share
29 Jun 2023 08:55

China CXO Has Reached a Crossroads - Time to Reconsider

Investors seem to have lost faith in China healthcare due to a plunge in CXO shares. This view is biased. It's time to clarify key logical points...

Logo
689 Views
Share
bearishWuxi Biologics
21 Jun 2023 08:55

Wuxi Biologics (2269.HK) - Investor Day Brings New Surprises

The information WuXi Bio disclosed on Investor Day was disappointing, leading to share price plunge.2023's growth is worrying. It's too early to...

Logo
568 Views
Share
14 May 2023 10:10

HK Short Interest Weekly: Ganfeng Lithium, Picc P&C, Jd, Bidu, Manulife

We analyzed the latest HK SFC report for aggregate short position as of May 5th and highlight short interest changes in Ganfenglithium, Picc P&C,...

Logo
384 Views
Share
x